ABSTRACT
Patients and animals with systemic lupus erythematosus (SLE) have abnormalities in their mesenchymal stem cells compared to healthy controls. The infusion of allogenic MSCs in animal lupus models and into patients with SLE appears to convey beneficial effects with virtually no toxicity. However, randomized controlled trials will be necessary to define the role of allogeneic MSC in patients with SLE
